Kolosis BIO® Expands Surgical Biologics Portfolio with Launch of APEXecm™
Kolosis®, the industry's leading pure-play surgical biologics company, today announced the addition of APEXecm™ to its growing portfolio of targeted solutions. The launch reflects Kolosis's approach to portfolio expansion — identifying technologies that address unmet clinical needs and delivering them with the commercial focus and technical expertise that only a dedicated biologics partner can provide.
